Expert opinion on the treatment of vulvovaginal atrophy with ospemifene based on new evidence

Article Obstetrics & Gynecology

Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA

R. Sanchez-Borrego et al.

Summary: This study aimed to evaluate the self-reported satisfaction of Spanish postmenopausal women currently treated for vulvovaginal atrophy (VVA) symptoms. The study found that treatment with ospemifene resulted in higher satisfaction levels and better treatment adherence compared to local hormone therapy and vaginal moisturizers.

CLIMACTERIC (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study

Beth L. Nordstrom et al.

Summary: This study compared the incidence of venous thromboembolism (VTE) among women treated with ospemifene and other selective estrogen receptor modulator (SERM) therapies, as well as untreated vulvar and vaginal atrophy (VVA) women. The results showed that there was no increase in the risk of VTE or other adverse events with the use of ospemifene in postmenopausal women.

THERAPEUTIC ADVANCES IN DRUG SAFETY (2022)

添加到收藏夹

Article Geriatrics & Gerontology

No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA) from a 2013-2020 US real world data

Bin Cai et al.

MATURITAS (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide

Angelica Linden Hirschberg et al.

Summary: Individualized approach is needed for the management of VVA, with topical low-dose estrogens being effective in alleviating symptoms. Non-hormonal preparations are recommended for long-term use for patients undergoing adjuvant endocrine therapies.

MATURITAS (2021)

添加到收藏夹

Editorial Material Clinical Neurology